Wall Street analysts predict that GALAPAGOS NV/S (NASDAQ:GLPG) will report ($0.29) earnings per share for the current quarter, Zacks reports. Four analysts have provided estimates for GALAPAGOS NV/S’s earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at ($0.90). GALAPAGOS NV/S reported earnings per share of $0.34 in the same quarter last year, which would suggest a negative year over year growth rate of 185.3%. The firm is scheduled to announce its next quarterly earnings results on Friday, April 3rd.
On average, analysts expect that GALAPAGOS NV/S will report full year earnings of $4.33 per share for the current year, with EPS estimates ranging from $2.71 to $7.29. For the next financial year, analysts forecast that the business will report earnings of ($1.84) per share, with EPS estimates ranging from ($8.33) to $1.68. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for GALAPAGOS NV/S.
GALAPAGOS NV/S (NASDAQ:GLPG) last posted its quarterly earnings results on Thursday, October 24th. The biotechnology company reported $8.72 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.41) by $10.13. The company had revenue of $715.97 million for the quarter, compared to the consensus estimate of $52.26 million. GALAPAGOS NV/S had a net margin of 32.09% and a return on equity of 25.34%.
Shares of GLPG stock traded up $3.52 during trading hours on Friday, hitting $209.23. The stock had a trading volume of 8,879 shares, compared to its average volume of 131,374. The firm has a market capitalization of $10.73 billion, a PE ratio of -317.81 and a beta of 1.58. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $206.00. The stock’s 50 day moving average is $181.18 and its 200 day moving average is $157.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.95 and a quick ratio of 8.95.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its position in shares of GALAPAGOS NV/S by 170.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 157 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of GALAPAGOS NV/S by 206.1% in the second quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 169 shares during the period. Ladenburg Thalmann Financial Services Inc. bought a new position in shares of GALAPAGOS NV/S in the second quarter worth $59,000. Quantamental Technologies LLC purchased a new stake in shares of GALAPAGOS NV/S in the 2nd quarter valued at about $74,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of GALAPAGOS NV/S during the 3rd quarter valued at about $109,000. Institutional investors and hedge funds own 15.28% of the company’s stock.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Article: 52- Week Highs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.